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urologist was more often performed in men than women 
(88.0 vs. 66.7%, p = 0.068), with a more favorable tumor de-
tection rate at first cystoscopy in men (96.0 vs. 50.0%, p < 
0.001).  Conclusions: Delayed referral patterns might lead to 
deferred diagnosis of UCB and consequently to adverse out-
come. Thus, primary care physicians might consider refer-
ring patients with bladder complaints to specialized care 
earlier.  © 2014 S. Karger AG, Basel 
 Introduction 
 The impact of female gender on outcome in urothelial 
carcinoma of the bladder (UCB) is a controversial matter. 
Although UCB is more frequent in men, women are more 
likely to suffer from an adverse survival outcome  [1, 2] .
 Various factors have been suggested to account for the 
sex differences of UCB, namely disparities in health care, 
environmental exposure to carcinogens, genetics, anato-
my, hormone balance, tumor biology and social life  [2] . 
Furthermore, delayed diagnosis of UCB due to misinter-
pretation of its early signs might also result in advanced 
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 Abstract 
 Objective: To analyze gender-specific differences regarding 
clinical symptoms, referral patterns and tumor biology prior 
to initial diagnosis of urothelial carcinoma of the bladder 
(UCB).  Methods: A consecutive series of patients with an ini-
tial diagnosis of UCB was included. All patients completed
a questionnaire on demographics, clinical symptoms and
referral patterns.  Results: In total, 68 patients (50 men, 18 
women) with newly diagnosed UCB at admission for trans-
urethral resection of bladder tumors were recruited. Dysuria 
was more often observed in women (55.6 vs. 38.0%, p = 
0.001). Direct consultation of the urologist was conducted 
by 84.0% of males and 66.7% of females (p = 0.120). One 
third of the women saw their general practitioner and/or gy-
necologist once or twice (p = 0.120) before referral to the 
urologist. Furthermore, women were significantly more of-
ten treated for urinary tract infections than men (61.1 vs. 
20.0%, p = 0.005). Cystoscopy at first presentation to the 
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tumor stages in female patients upon initial diagnosis of 
UCB  [3–6] .
 Therefore, the aim of our study was to validate the 
findings of a previously presented questionnaire-based 
study incorporating a comparative analysis of gender-as-
sociated differences in terms of symptoms, referral pat-
terns and therapy before initial diagnosis of UCB within 
a prospective, double-center study  [5] .
 Patients and Methods 
 Patient Selection 
 The present prospective cohort study comprised a total of 68 
consecutive patients undergoing transurethral resection of blad-
der tumor (TUR-BT) for newly diagnosed UCB at two tertiary re-
ferral centers from 2010 to 2013. After obtaining informed consent 
for surgery and study participation, all of the patients received a 
questionnaire before TUR-BT. The data from the Bolzano patients 
(n = 46), which have already been published in Henning et al.’s 
study  [5] , were excluded prior to analysis within the present study.
 Questionnaire 
 The five-page questionnaire was identical to the previously 
published questionnaire developed by Henning et al.  [5] ( fig. 1 ). 
Information was collected on smoking habits and profession. The 
presence of clinical symptoms was evaluated, specifically hematu-
ria, dysuria and/or bladder pain and treatment of urinary tract in-
fection (UTI) within a 12-month period prior to the initial diag-
nosis of UCB. Furthermore, nocturia and urgency within 4 weeks 
prior to the diagnosis of UCB were also assessed. The other items 
addressed consultation and treatment before referral to the urolo-
gist. Our study group was questioned regarding the frequency of 
visiting their general practitioner (GP) and/or gynecologist due to 
bladder complaints prior to referral to the urologist. In addition, 
we assessed the frequency of urological consultations before cys-
toscopy was conducted and whether a tumor was observed at ini-
tial cystoscopy.
 Pathologic Evaluation 
 All of the specimens were analyzed according to standard 
pathologic procedures at each institution. Tumors were staged ac-
cording to the 2010 American Joint Committee on Cancer TNM 
classification and tumor grading was assessed according to the 
2004 WHO classification  [6] .
 Statistical Analysis 
 The Kolmogorov-Smirnov test was used to evaluate the normal 
distribution of continuous variables. Continuous variables are pre-
sented as mean values with standard deviations (SD) or as a me-
dian with interquartile ranges (IQR), according to the type of dis-
tribution. The Wilcoxon rank sum test (Mann-Whitney U; two cat-
egories) and the Kruskal-Wallis test (three or more categories) was 
utilized for non-normally distributed variables. Comparison be-
tween categorical variables was performed using Fisher’s exact and 
χ 2 test. Statistical analyses were conducted with SPSS Statistics ® 20 
(SPSS, IBM Corp., Armonk, N.Y., USA). The reported p values are 
two-sided with the statistical significance level set at p < 0.05.
 Results 
 Patient Characteristics 
 A total of 50 male patients (73.5%) and 18 female pa-
tients (26.5%) with a respective median age of 68 (IQR 
58.8) and 69 (IQR 63.8) years entered this prospective 
cohort study. In the male cohort, 36.0% were non-smok-
ers, 26.0% active smokers and 38.0% former smokers
(p = 0.425). In contrast, 27.8% of the female patients were 
non-smokers, 16.7% were active smokers and 55.6% were 
former smokers (p = 0.425). In terms of profession, 32.4% 
of our population were office workers, of whom 32.0% 
were male and 33.3% female (p = 0.001).  Table 1 gives a 
detailed summary of the descriptive characteristics of our 
cohort.
 Clinical Symptoms 
 Gross hematuria within 12 months prior to UCB diag-
nosis was observed in 70.0% of men and 61.1% of women 
(p > 0.05). The mean time interval between the incidence 
of gross hematuria and diagnosis of UCB was 11.3 (SD 
4.5) months in men and 10.3 (SD 6.7) months in women 
(p > 0.05). Dysuria and/or bladder pain within 4 weeks 
before initial diagnosis was reported in 38.0% of the male 
and 55.6% of the female patients (p > 0.05). Nocturia 4 
weeks prior to UCB diagnosis was reported in 62.0% of 
the males and 50.0% of the females (p > 0.05). Urgency 
was monitored in 62.0% of the men and 61.1% of the 
women (p > 0.05) ( table 1 ,  fig. 2 ).
 Referral Patterns 
 Direct consultation of a urologist was initiated by 
84.0% of the men vs. 66.7% of the women. 16.0% of the 
men and 33.4% of the women saw their GP and/or gyne-
cologist once or twice before referral to the urologist (p = 
0.120). Symptomatic treatment by the GP and/or gyne-
cologist was administered once or more in 38.0% of the 
men and in 44.5% of the women (p = 0.868). Treatment 
of UTI within 12 months prior to initial UCB diagnosis 
was given to 20.0% of the men and to 61.1% of the wom-
en (p = 0.005). At first urological consultation, cystoscopy 
was performed in 88.0% of the men vs. 66.7% of women 
(p = 0.07). Detection of bladder tumor at initial cystos-
copy was observed in 96.0% of the men and in 50.0% of 
the women (p < 0.001) ( table 1 ).
 Tumor Stage Distribution in Men and Women 
 Men significantly more often presented with pTa (58.0 
vs. 33.3%), pT1 (16.0 vs. 5.6%) and  ≥ pT2 (18.0 vs. 11.1%) 
than women, while women were significantly more likely 
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Name:
Date of birth:
Section I. (To be completed by the treating urologist)
Date of interview: 
Date of TUR-BT:
Histopathology:       pT [  ]
                                 Low grade [  ]       High grade [  ]
                                 Concomitant CIS       Yes [  ]       No [  ]
Section II. (To be completed by the patient)
Smoking habits
[  ] I am a non-smoker.
[  ] I am a smoker. I have been smoking since ____ (year) around ____ cigarettes per day.
[  ]  I am an ex-smoker, I stopped smoking in ____ (year). Prior to that, I smoked around ____ cigarettes
per day.
Profession
Which profession(s) did you have in the last 20 – 30 years of your working life? (multiple choices are
possible)
[  ] Office work
[  ] Painter/limer/varnisher
[  ] Hairdresser
[  ] Dye industry
[  ] Motor mechanic
[  ] Housewife
[  ] Other _________________
Symptoms
(1) Within the last 12 months, did you notice visible blood in your urine?
Yes [  ]       No [  ]
If yes, when was the first time of occurrence of visible blood in your urine?
____ months ago
(2) Within the last 12 months, did you experience episodes of bladder pain and/or a burning sensation 
when passing urine?
Yes [  ]       No [  ]
(3) Within the last 4 weeks, did you experience episodes of permanent or recurring unpleasant urge to 
pass urine? 
Yes [  ]       No [  ]
(4) Within the last 4 weeks, did you have to get up more often than twice a night to pass urine?
Yes [  ]       No [  ]
Consultations and treatments
(5) How often did you consult a general practitioner and/or a gynecologist regarding your complaints 
before you were referred to a urologist for further evaluation?
[  ] Never, I directly consulted a urologist
[  ] Once or twice
[  ] Three times or more often
(6) How often did you receive symptomatic treatment (e.g. pain medication) regarding your
complaints before you were referred to a urologist for further evaluation?
[  ] Never, I was directly referred to a urologist
[  ] Once or twice
[  ] Three times or more often
(Continued on next page.)
1
 Aziz et al.
 
 Urol Int 2015;94:37–44 
DOI: 10.1159/000363334
40
than men to be associated with carcinoma in situ (CIS) 
only (50.0 vs. 8.0%, p = 0.002 for all). High-grade tumor 
distribution was 64.0% in men vs. 61.1% in women (p > 
0.05). Tumor stage distribution in detail can be seen in 
 table 2 .
 Discussion 
 Data on gender-associated differences in referral pat-
terns at the time of initial UCB diagnosis are rare. The 
current study revealed several disparities in clinical symp-
toms, referral patterns, tumor stages and grading between 
both sexes. In terms of clinical symptoms, gross hematu-
ria was more frequently observed in men than women; 
women suffered more often from dysuria and/or bladder 
pain, while nocturia was more prevalent in men. Further-
more, female patients were more often treated for voiding 
disorders or presumed UTIs without further examination 
or prompt referral to specialized care by the urologist 
compared to men. In addition, tumor detection by the 
urologist was more often observed at second cystoscopy 
in females, while in the vast majority of the male popula-
tion, bladder tumors were detected during first cystos-
copy.
 The findings of the present study are largely congruent 
with the findings of Henning et al.  [5] . The authors pre-
sented a questionnaire-based study in which they also 
found that women were more likely to be treated by their 
GP or gynecologist for voiding complaints and UTIs in-
stead of being directly referred to a urologist. In terms of 
gender-related differences in clinical symptoms, their re-
sults are mostly in line with our findings with respect to 
dysuria and/or bladder pain and urgency. The differences 
between the results in the present and Henning et al.’s 
cohort refer to the frequency of hematuria and nocturia, 
which both were more frequently observed in men than 
women in our study population and conversely in Hen-
ning et al.’s study. Furthermore, women in Henning et 
al.’s cohort more often presented with stage  ≥ pT2, while 
we observed more stage  ≥ pT2 (18.0 vs. 11.1%) in men and 
no differences regarding tumor grade distribution (64.0 
vs. 61.1%). However, the comparability of Henning et al.’s 
and our findings is limited due to the small sample size in 
our population. Nevertheless, the gender distribution in 
Henning et al.’s cohort (n = 168), with 77.0% male and 
23.0% female patients, and in our cohort (n = 68), with 
73.5% male and 26.5% female patients, was similar  [2] . 
Moreover, the questionnaire developed by Henning et al. 
(7) How often did you receive treatment for bladder infections from your general practitioner
and/or gynecologist before you were referred to a urologist for further evaluation? 
[  ] Never
[  ] Once or twice
[  ] Three times or more often
(8) Did the urologist perform a cystoscopy at the first consultation? 
Yes [  ]       No [  ]
(9) Was the bladder tumor discovered at the first cystoscopy performed?
Yes [  ]       No [  ]
80
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 Fig. 2. Clinical symptoms within 12 months prior to initial diag-
nosis of UCB. 
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 Fig. 1. Questionnaire. 
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 Table 1.  Descriptive characteristics of 68 patients with an initial diagnosis of UCB
Entire population Men Women p
(n = 68) (n = 50) (n = 18)
Demographics
Age, years (median; IQR) 68 (61; 76) 68 (58; 76) 69 (63; 74) 0.583
Smoking habits
Non-smoker 23 (33.8%) 18 (36.0%) 5 (27.8%)
Smoker 16 (23.5%) 13 (26.0%) 3 (16.7%) 0.425
Ex-smoker 29 (42.6%) 19 (38.0%) 10 (55.6%)
Number of pack-years, smokers (mean ± SD) 34 ± 19 34 ± 20 32 ± 14 0.893
Number of pack-years, ex-smokers (mean ± SD) 24 ± 15 25 ± 19 21 ± 4 0.772
Profession
Office work 22 (32.4%) 16 (32.0%) 6 (33.3%)
Painter/limer/varnisher 3 (4.4%) 1 (2.0%) 2 (11.1%)
Hairdresser 0 0 0
Dye industry 1 (1.5%) 0 1 (5.6%) 0.001
Motor mechanic 3 (4.4%) 3 (6.0%) 0
Housewife 4 (5.9%) 0 4 (22.2%)
Other 35 (51.5%) 5 (10.0%) 5 (27.8%)
Clinical symptoms
Presence of gross hematuria within the last 12 months
Yes 46 (67.6%) 35 (70.0%) 11 (61.1%) 0.562No 22 (32.4%) 15 (30.0%) 7 (38.9%)
Time from first episode of gross hematuria to 11.0 ± 4.0 11.3 ± 4.5 10.3 ± 6.7 0.351
initial diagnosis of UCB, months
Presence of dysuria and/or bladder pain
Yes 46 (67.6%) 19 (38.0%) 10 (55.6%) 0.268No 22 (32.4%) 31 (62.0%) 8 (44.4%)
Incidence of nocturia within the last 4 weeks
Yes 40 (58.8%) 31 (62.0%) 9 (50.0%) 0.413No 28 (41.2%) 19 (38.0%) 9 (50.0%)
Incidence of urgency within the last 4 weeks
Yes 42 (61.8%) 31 (62.0%) 11 (61.1%) 0.947No 26 (38.2%) 19 (38.0%) 7 (38.9%)
Consultation and treatment
Frequency of treatment by GP/gynecologist before referral to urologist
Never, initial treatment by urologist 54 (79.4%) 42 (84.0%) 12 (66.7%)
Once or twice 13 (19.1%) 8 (16.0%) 5 (27.8%) 0.120
Three times or more often 1 (1.5%) 0 1 (1.5%)
Symptomatic treatment before referral to urologist
Never, initial treatment by urologist 41 (60.3%) 31 (62.0%) 10 (55.6%)
Once or twice 11 (16.2%) 8 (16.0%) 3 (16.7%) 0.868
Three times or more often 16 (23.5%) 11 (22.0%) 5 (27.8%)
Treatment of UTI within the last 12 months
Never 47 (69.1%) 40 (80.0%) 7 (38.9%)
Once or twice 14 (20.6%) 7 (14.0%) 7 (38.9%) 0.005
Three times or more often 7 (10.3%) 3 (6.0%) 4 (22.2%)
Cystoscopy at first consultation
Yes 56 (82.4%) 44 (88.0%) 12 (66.7%) 0.068No 12 (17.6%) 6 (12.0%) 6 (33.3%)
Detection of bladder tumor at first cystoscopy
Yes 57 (83.3%) 48 (96.0%) 9 (50.0%) <0.001No 11 (16.2%) 2 (4.0%) 9 (50.0%)
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was implemented in our cohort with a response rate of 
nearly 100%.
 The gender-related delay of initial UCB diagnosis 
might be due to the misinterpretation of hematuria and 
voiding complaints. Several studies have shown that he-
maturia is a strong predictor for genitourinary malig-
nancies, especially bladder cancer  [7] . Therefore, further 
evaluation of hematuria is always warranted, since up to 
92% of cancers detected during the work-up of hematuria 
are still locally staged and thus potentially curable  [8] . 
Furthermore, urgency is often misinterpreted as a symp-
tom for UTI that incites the treating physician to pre-
scribe antibiotics and/or estrogen medication in elderly 
women  [9] . A Swedish study demonstrated that referral 
to the urologist was delayed in women with urgency and 
hematuria. Thus, women presented with an advanced 
stage of UCB at initial diagnosis  [10] . Nieder et al.  [9] 
conducted a questionnaire-based survey to analyze prac-
tice patterns of the evaluation of hematuria by primary 
care physicians. They observed that up to 31% of patients 
presenting with gross hematuria were not referred to a 
urologist for specialized care. Similar results were report-
ed by Yafi et al.  [11] , who demonstrated that only 48.6% 
of the evaluated primary care physicians would refer a 
postmenopausal woman with two consecutive events of 
significant microscopic hematuria to a urologist. Johnson 
et al.  [12] showed in their findings with 926 healthcare 
plan participants that men with initial or recurrent epi-
sodes of hematuria are advised to consult the urologist 
more often than women, which is underlined by our find-
ings. In Johnson et al.’s study, women were more likely to 
turn to the GP and/or gynecologist than men before refer-
ral to the urologist, which is also in line with our observa-
tions. When taking the aforementioned studies and our 
cohort into consideration, higher awareness of hematuria 
and urgency is required on the part of GPs and gynecolo-
gists to avoid a delayed diagnosis of UCB, which is associ-
ated with an adverse outcome  [13] .
 Several hypotheses have been generated to explain the 
underlying reasons for the gender-related disparities in 
UCB, including anatomy and hormonal involvement 
 [13] . In non-muscle-invasive bladder cancer, Kluth et al. 
 [14] reported that female gender was associated with a 
higher risk of disease recurrence. Similar findings were 
observed by the Club Urológico Español de Tratamiento 
Oncológico  [15] , Palou et al.  [16] and Keck et al.  [17] , who 
demonstrated that female gender was an independent 
predictor of disease recurrence, progression and im-
paired overall survival. On the other hand, Sylvester et al. 
 [18] did not find an independent impact of gender within 
EORTC trials comprising roughly 2,600 patients with Ta 
or T1 non-muscle-invasive bladder cancer after TUR-BT. 
In muscle-invasive bladder cancer, Kluth et al.  [19] , in a 
large multicenter series with roughly 1,600 female pa-
tients, previously showed that female gender was signifi-
cantly associated with disease recurrence and cancer-spe-
cific mortality. Mungan et al.  [20] reported impaired can-
cer-specific survival in women across all stages of bladder 
cancer within an epidemiological survey comprising all 
types of therapy performed from 1973 to 1996. Horst-
mann et al.  [21] described a significantly reduced 10-year 
survival in women undergoing radical cystectomy from 
1969 to 1997. In addition, two further multicenter studies 
also found an impaired cancer-specific survival in wom-
en, particularly when lymphovascular invasion was pres-
ent  [22, 23] . Interestingly, higher tumor stages were only 
seen in our male population. Furthermore, 50.0% of the 
female patients in our cohort presented with CIS only. A 
subgroup analysis (data not shown) revealed that in 33.3% 
of the latter patients, bladder tumor was not detected at 
initial cystoscopy. Although showing statistical signifi-
cance, our findings in terms of higher tumor stage distri-
Entire population
(n = 68) 
Men
(n = 50)
Women
(n = 18)
p
Pathologic tumor stage at initial TUR-BT
CIS only 13 (19.1%) 4 (8.0%) 9 (50.0%)
0.002pTa 35 (51.5%) 29 (58.0%) 6 (33.3%)pT1 9 (13.2%) 8 (16.0%) 1 (5.6%)
≥pT2 11 (16.2%) 9 (18.0%) 2 (11.1%)
Tumor grading at initial TUR-BT
Low grade 25 (36.8%) 18 (36.0%) 7 (38.9%) 0.827High grade 43 (63.2%) 32 (64.0%) 11 (61.1%)
 Table 2.  Gender-specific associations of 
pathologic tumor stage and grade in 68 
patients with an initial diagnosis of UCB
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bution between men and women are limited due to the 
small sample of  ≥ pT2 tumors.
 Evaluation of urinary cytology samples at the time of 
first cytology would have been reasonable to detect CIS 
earlier  [24] . To what extent other tests in addition to uri-
nary cytology might lead to a benefit in the early diagno-
sis of bladder cancer still remains a matter of debate. 
Here, several studies have evaluated the efficacy of uri-
nary markers as non-invasive tools. Bassi et al.  [25] stated 
that most of the markers tend to be less specific but more 
favorable in terms of sensitivity compared to urinary cy-
tology. Another comparative study focusing on NMP22, 
BTA stat test and cytology ascribed NMP22 a higher sen-
sitivity than cytology  [26] . Sagnak et al.  [27] recommend 
NMP22 as a cost-effective method in combination with 
upper tract ultrasonography instead of urine cytology for 
low-risk patients with asymptomatic microscopic hema-
turia. Nevertheless, urinary cytology shows excellent tu-
mor detection of relevant high-grade urothelial carcino-
ma  [28] . Hence, it will most likely continue to be used in 
the initial evaluation of patients with suspected urological 
malignancy until new markers are indicated to be opti-
mal, showing favorable sensitivity and specificity  [29] .
 Our study is not devoid of limitations. The data are 
based on a non-validated questionnaire and are poten-
tially hampered by a recall bias regarding the first onset 
of clinical symptoms prior to diagnosis. Furthermore, we 
were not able to provide data on oncological outcome. 
Finally, our findings are limited by the small sample size. 
However, our data were assessed in a prospective fashion 
from two tertiary academic centers from two European 
countries.
 Conclusions 
 This prospective cohort study revealed differences be-
tween referral patterns for men and women. Women pre-
senting with clinical symptoms such as hematuria and 
voiding disorders are frequently misinterpreted by the 
treating GP and/or gynecologist; this contributes to a de-
ferred diagnosis of UCB, which can be associated with 
poor outcome. Primary care physicians should be aware 
of this scenario and therefore consider early referral to 
specialized care, particularly in patients presenting with 
treatment-refractory bladder symptoms.
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